
Bioengineered Skin Microbiota for Cutaneous Mitigation of Netherton SyndromeAward last edited on: 2/26/2019
Sponsored Program
SBIRAwarding Agency
NIH : NIAMSTotal Award Amount
$225,000Award Phase
1Solicitation Topic Code
-----Principal Investigator
Travis M WhitfillCompany Information
Phase I
Contract Number: ----------Start Date: ---- Completed: ----
Phase I year
2018Phase I Amount
$225,000Project Terms:
Address; Affect; antimicrobial peptide; Area; Asthma; Bacteria; Bacterial Proteins; base; Biochemical; Biological Assay; Biomedical Engineering; Birth; Businesses; Calcineurin inhibitor; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; commensal bacteria; commensal microbes; Complement; Compliance behavior; corticosteroid inhibitor; cost; CRISPR/Cas technology; Cutaneous; Development; Disease; disease phenotype; DNA Sequence Alteration; Drug Delivery Systems; Embryo; Engineered Probiotics; Engineering; experimental study; Foundations; Functional disorder; Genes; Genomic medicine; Goals; Hair; Hair shaft structure; Histologic; Human; Hypersensitivity; IgE; Immune system; Immunologic Deficiency Syndromes; immunoregulation; improved; In Situ; In Vitro; in vitro activity; in vitro Assay; in vitro testing; indexing; Infant; Infection; inhibitor/antagonist; innovation; interest; Intravenous Immunoglobulins; keratinocyte; Kininogenase; Laboratories; Lesion; Life; loss of function mutation; Measures; Methods; Microbe; microbiome; microbiome therapeutics; Modeling; Morphology; mortality; mouse model; Mus; Mutation; Neonatal; novel; novel strategies; novel therapeutics; outcome forecast; pathogen; Patients; Peptide Hydrolases; Phenotype; Plasmids; pre-clinical; Pre-Clinical Model; preclinical trial; Preparation; Production; Property; Proteins; Protocols documentation; Rare Diseases; Reapplication; Recombinants; Recurrence; Regulatory T-Lymphocyte; Reporting; Research Project Grants; residence; Resources; Serine Protease; Serine Proteinase Inhibitors; Severities; Severity of illness; Skin; skin disorder; skin microbiome; skin microbiota; Small Business Innovation Research Grant; Staphylococcus aureus; Staphylococcus epidermidis; Symptoms; Syndrome; System; Testing; The Jackson Laboratory; Therapeutic; therapeutic protein; Time; Topical application; Topical Corticosteroids; Treatment Cost; Treatment Efficacy;
Phase II
Contract Number: ----------Start Date: ---- Completed: ----